Han Kun represents Biomerieux in establishing strategic cooperation with Accunome
December, 2022 - Beijing, Mainland China
In December 2022, Biomerieux and Jiaxing Accunome Biotechnology Co., Ltd. ("Accunome") entered into a strategic partnership upon concluding both a strategic investment agreement and an exclusive distribution agreement. The deal allows Biomerieux to embark on in-depth collaboration with Accunome to expedite the expansion of Biomerieux's molecular diagnostics business in China through DXcellence12, Accunome's fully automated molecular diagnostics platform and ancillary reagent tubes for the platform. In return, Accunome will expand the market presence for its products via Biomerieux's mature business channels in the Chinese market.
Han Kun represented Biomerieux in its execution of the strategic investment agreement and the exclusive distribution agreement with Accunome. Owing to the firm's extensive experience and profound understanding of the medical device industry, Han Kun not only provided legal services throughout all stages of the transaction process, such as deal structure design, contract negotiation, and project consummation, but was deeply involved in negotiating commercial terms for the strategic cooperation, which requires a high level of specialized expertise.
About Biomerieux:(https://www.biomerieux.com.cn/)
Biomerieux has been committed to providing advanced diagnostic solutions for better patient care in China, with special expertise in infectious diseases, which has been the focus of both healthcare providers and patients in recent years. Advanced bio-diagnostic products will safeguard public health by saving time and improving quality of diagnosis to enable sooner identification, control, and treatment of infectious diseases.
